Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Retained Earnings: 2015-2024

Historic Retained Earnings for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to -$1.5 billion.

  • Editas Medicine's Retained Earnings fell 14.04% to -$1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 billion, marking a year-over-year decrease of 14.04%. This contributed to the annual value of -$1.5 billion for FY2024, which is 19.25% down from last year.
  • As of FY2024, Editas Medicine's Retained Earnings stood at -$1.5 billion, which was down 19.25% from -$1.2 billion recorded in FY2023.
  • Editas Medicine's 5-year Retained Earnings high stood at -$665.2 million for FY2020, and its period low was -$1.5 billion during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$1.2 billion (2023), whereas its average is -$1.3 billion.
  • Data for Editas Medicine's Retained Earnings shows a maximum YoY declined of 28.94% (in 2021) over the last 5 years.
  • Over the past 5 years, Editas Medicine's Retained Earnings (Yearly) stood at -$665.2 million in 2020, then dropped by 28.94% to -$857.7 million in 2021, then declined by 25.70% to -$1.1 billion in 2022, then declined by 14.21% to -$1.2 billion in 2023, then dropped by 19.25% to -$1.5 billion in 2024.